Loading organizations...
Loading organizations...
Deciphera Pharmaceuticals is a technology company.
Deciphera Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and delivers innovative oncology medicines. The company leverages its proprietary switch-control kinase inhibitor platform, grounded in deep expertise in kinase biology, to discover and advance a pipeline of drug candidates. This technical approach focuses on precisely targeting protein kinases to address cancer mechanisms and overcome drug resistance.
The company was founded in 2003 by Daniel L. Flynn, Ph.D. His initial vision centered on establishing an environment that fostered true innovation and results, aiming to build an infrastructure and culture characterized by ethical standards and accountability. This foundational insight continues to guide the company's research and development efforts.
Deciphera Pharmaceuticals serves patients battling various forms of cancer. Its overarching mission is to improve the lives of these individuals by discovering, developing, and delivering important new medicines. The company is driven by a commitment to provide novel treatments through targeted kinase inhibition, striving to offer new hope and enhanced quality of life for cancer patients globally.
Deciphera Pharmaceuticals has raised $217.0M across 3 funding rounds.
Deciphera Pharmaceuticals has raised $217.0M in total across 3 funding rounds.
Deciphera Pharmaceuticals has raised $217.0M in total across 3 funding rounds.
Deciphera Pharmaceuticals's investors include Redmile Group, Sphera Healthcare, Viking Global Investors, New Leaf Venture Partners, Michael Ross, Access Biotechnology.
Deciphera Pharmaceuticals is a biopharmaceutical company, not a technology company in the traditional sense, focused on discovering, developing, and commercializing targeted therapies to improve outcomes for cancer patients by overcoming drug resistance mechanisms.[1][3] Its lead product, QINLOCK (ripretinib), is an FDA-approved switch-control kinase inhibitor for fourth-line treatment of gastrointestinal stromal tumors (GIST), with ongoing studies like INTRIGUE for second-line GIST.[1][3] The company also advances vimseltinib (ROMVIMZA™), approved by the European Commission for tenosynovial giant cell tumor (TGCT), and preclinical candidates like DCC-3116 for RAS/RAF mutant cancers.[1][5] Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera became a subsidiary of Ono Pharmaceutical Co., Ltd. in June 2024, with an international hub in Zug, Switzerland, leveraging biotech ecosystems for global operations.[1][2]
Serving oncology patients worldwide, Deciphera addresses unmet needs in hard-to-treat cancers through its proprietary switch-control kinase inhibitor platform, which targets key resistance pathways to enhance response durability.[1][3] Growth momentum includes recent approvals like ROMVIMZA™, positive Phase 2a data for sapablursen in polycythemia vera presented at ASH 2025, and multiple updates at CTOS 2025, alongside recognition as a Great Place to Work.[4][5]
Deciphera Pharmaceuticals was founded in 2003 in Waltham, Massachusetts, building on expertise in kinase biology to pioneer switch-control kinase inhibitors for cancer.[1][3] The company's idea emerged from deep research into drug resistance mechanisms limiting existing therapies, leading to a platform that modulates kinase switches for more precise targeting.[3] Early traction came with the development of QINLOCK, approved by the FDA for advanced GIST, marking a pivotal milestone in commercializing innovative oncology drugs.[1][3]
Key evolution includes expanding its pipeline with vimseltinib for TGCT and sapablursen, while establishing an international headquarters in Zug, Switzerland in 2021 to manage global non-U.S. operations amid a strong biotech talent pool.[2] In June 2024, acquisition by Ono Pharmaceutical integrated Deciphera as a subsidiary, enhancing resources for worldwide expansion under directors like Toichi Takino and Masayuki Tanigawa.[1]
Deciphera rides the wave of precision oncology, where targeted kinase inhibitors combat resistance in solid tumors amid rising demand for durable cancer therapies.[1][3] Timing aligns with biotech hubs like Greater Zurich Area's ecosystem—home to Roche and Novartis—facilitating U.S. firms' European expansion via talent, infrastructure, and tax advantages.[2] Market forces favoring Deciphera include aging populations driving cancer incidence, regulatory nods like ROMVIMZA™ approval, and partnerships post-Ono acquisition amplifying global reach.[1][5]
The company influences the ecosystem by advancing switch-control technology, inspiring kinase-focused innovation, and contributing to clinical advancements shared at forums like ASH and CTOS, while its Zug presence bolsters Europe's biotech leadership.[2][5]
Deciphera is poised for pipeline acceleration, with sapablursen data from ASH 2025 and CTOS presentations signaling potential expansions into polycythemia vera and connective tissue tumors.[5] Trends like AI-driven drug discovery and combination therapies will shape its trajectory, leveraging Ono's support for faster global approvals and commercialization.[1] Influence may evolve through broader adoption of its platform, positioning Deciphera as a key player in resistance-breaking oncology—transforming patient lives from a biopharma leader once mislabeled as mere "technology."
Deciphera Pharmaceuticals has raised $217.0M across 3 funding rounds. Most recently, it raised $52.0M Series C in June 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2017 | $52.0M Series C | Redmile Group, Sphera Healthcare, Viking Global Investors | New Leaf Venture Partners |
| Jan 5, 2016 | $90.0M Series B | Michael Ross | |
| Sep 1, 2015 | $75.0M Series B | Access Biotechnology |